SALT LAKE CITY–The University of Utah (the U), ARUP Laboratories, and Techcyte Inc. announced today that they have formed a partnership to develop NanoSpot.AI, a less than five-minute, easy-to-administer SARS-CoV-2 antibody test. NanoSpot.AI is estimated to be significantly less expensive to manufacture than other SARS-CoV-2 antibody tests, so it has the potential to be considerably more affordable than currently available tests, making it possible to extend the test to every corner of the world
The patent-pending NanoSpot.AI is performed on a spot of blood obtained through a finger prick. Individuals then receive their test results on their mobile phones. The test could be used around the globe to help prioritize who should receive SARS-CoV-2 vaccinations, or to easily and quickly detect whether individuals have some immunity against COVID-19 for travel or immigration purposes. Clinical studies validating NanoSpot.AI are currently underway.
“Other antibody tests are available and are very good, but it takes time to get test results back and they’re relatively expensive,” said Hans Haecker, MD, PhD, who codeveloped NanoSpot.AI with Vanessa Redecke, MD, PhD. Both are professors in the U Pathology Department Division of Microbiology and Immunology. “Based on what we know so far, we believe NanoSpot.AI checks all the boxes,” Haecker said. “Because it is simple, fast, and very affordable, it can be done anywhere without specialized equipment, creating the potential for us to have an impact on human health around the world.”
The partners in NanoSpot.AI created a video that explains the science behind the assay, demonstrates how the test is administered, and provides details about the AI used to analyze and confirm test results.
“As a national reference laboratory, ARUP has a wide view of laboratory diagnostics,” said Mark Astill, ARUP director of Research and Development. “The expertise and experience we bring enabled what may be the first instance of combining seemingly disparate elements to produce a rapid, economical, QR-code-curated, consistent, point-of-care result.”
All NanoSpot.AI test components are provided in a self-contained kit. The person administering the test places droplets of blood in three small spots on a ready-to-use card. One of the spots displays the test result while the other two confirm the test was properly run. Antibodies against SARS-CoV-2 are quickly apparent because the blood spot begins to separate within seconds when the test result is positive.
To ensure accurate results, the person administering the test uses a mobile phone to take a photograph of the card, which is then transmitted to Techcyte for analysis using the company’s AI-based image analysis tool. Techcyte, a U startup company, is a developer of artificial intelligence (AI)-based image analysis solutions for the diagnostics industry.
Techcyte CEO Ben Cahoon said the company modified its digital diagnostics platform to work with images captured by mobile phones rather than microscopes for NanoSpot.AI.
“Our platform breaks each blood spot into thousands of features that the AI uses to statistically determine which specimens are positive for SARS-CoV-2 antibodies,” Cahoon said.
Haecker said the assay can be easily adapted to test for antibodies to SARS-CoV-2 variants as new mutations emerge. The test can be viewed as a platform because it and the AI can be developed to test for antibodies against other viruses.
“This has been an extremely effective partnership and collaboration between the U, ARUP and Techcyte, demonstrating how university technology can be fast-tracked by collaborating with the right partners,” said Aaron Duffy, technology manager at the U’s Partners for Innovation, Ventures, Outreach & Technology (PIVOT) Center. PIVOT Center, which manages the U’s innovations and drives them to market, is now seeking partners to launch Nanospot.AI.
For more information, contact Duffy at PIVOT Center (email@example.com); Astill at ARUP (firstname.lastname@example.org); or Cahoon at Techcyte (email@example.com).